Trial Profile
Phase I open label study of a subcutaneous (SC) form of CT-P13 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Infliximab
- Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- 03 Nov 2017 New trial record
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week